Intersect ENT Announces Closing Of Its Initial Public Offering
MENLO PARK, Calif., July 29, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions, today announced the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $11.00 per share, including 750,000 shares sold pursuant to the underwriters' option to purchase additional shares. The Company's shares began trading on The NASDAQ Global Market on July 24, 2014 under the ticker symbol "XENT."
J.P. Morgan Securities LLC and Piper Jaffray & Co. acted as joint book-running managers for the offering. Leerink Partners and Wedbush PacGrow Life Sciences acted as co-managers. A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on July 23, 2014. The offering was made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus relating to these securities may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or from Piper Jaffray & Co., 800 Nicollet Mall, Suite 1000, Minneapolis, MN 55402, Telephone: 800-747-3924, Email: prospectus@pjc.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Intersect ENT
Intersect ENT, Inc. is a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions. Intersect ENT's initial products, PROPEL and PROPEL mini, are the first and only drug-eluting implants approved by the U.S. Food and Drug Administration for use in patients with chronic sinusitis.
The statement contained in this press release regarding the anticipated closing date of the offering is a "forward-looking statement" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statement is subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks and uncertainties relating to Intersect ENT and its business can be found in the "Risk Factors" section of Intersect ENT's Amendment No. 3 to Form S-1, filed with the SEC on July 18, 2014 related to the offering. Intersect ENT undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in Intersect ENT's expectations.
CONTACT: Media Contact: Nicole Osmer 650.454.0504 nicole.osmer@intersectent.com Investor Contact: Jeri Hilleman 650.641.2105 ir@intersectent.com 
Help employers find you! Check out all the jobs and post your resume.